BR112017008280A2 - método para o tratamento de um paciente - Google Patents
método para o tratamento de um pacienteInfo
- Publication number
- BR112017008280A2 BR112017008280A2 BR112017008280-2A BR112017008280A BR112017008280A2 BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2 BR 112017008280 A BR112017008280 A BR 112017008280A BR 112017008280 A2 BR112017008280 A2 BR 112017008280A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- treating
- cell carcinoma
- hpv
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462068332P | 2014-10-24 | 2014-10-24 | |
| US62/068,332 | 2014-10-24 | ||
| PCT/US2015/057150 WO2016065281A1 (en) | 2014-10-24 | 2015-10-23 | Cancer and skin lesion treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017008280A2 true BR112017008280A2 (pt) | 2018-01-02 |
Family
ID=55761638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017008280-2A BR112017008280A2 (pt) | 2014-10-24 | 2015-10-23 | método para o tratamento de um paciente |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10238729B2 (https=) |
| EP (1) | EP3209676A4 (https=) |
| JP (1) | JP6663438B2 (https=) |
| KR (1) | KR102285401B1 (https=) |
| CN (1) | CN107001430A (https=) |
| AU (1) | AU2015335652B2 (https=) |
| BR (1) | BR112017008280A2 (https=) |
| CA (1) | CA2965498A1 (https=) |
| CL (1) | CL2017001008A1 (https=) |
| IL (1) | IL251825B2 (https=) |
| MX (1) | MX395186B (https=) |
| MY (1) | MY195018A (https=) |
| PH (1) | PH12017500754A1 (https=) |
| SG (1) | SG11201703262UA (https=) |
| WO (1) | WO2016065281A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018067550A2 (pt) * | 2016-02-27 | 2019-10-01 | Hpvvax, Llc. | métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2284559T3 (es) * | 2001-03-23 | 2007-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Genes y proteinas e6 y e7 modificados del vph utiles como vacuna. |
| GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
| US20060222656A1 (en) * | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| GB0222953D0 (en) * | 2002-10-03 | 2002-11-13 | Glaxo Group Ltd | Novel Compounds |
| PT1572233E (pt) | 2002-12-20 | 2011-06-07 | Glaxosmithkline Biolog Sa | Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
| JP2008502633A (ja) * | 2004-06-16 | 2008-01-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン |
| US8399610B2 (en) | 2004-08-05 | 2013-03-19 | University College Cardiff Consultants Limited | HPV vaccine comprising peptides from host cell proteins |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| CA2679720A1 (en) * | 2007-03-09 | 2008-09-18 | Merck & Co., Inc. | Papillomavirus vaccine compositions |
| CN101530612A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 16型重组人乳头瘤病毒疫苗 |
| CN101530614A (zh) * | 2008-03-10 | 2009-09-16 | 北京康乐卫士生物技术有限公司 | 五价重组人乳头瘤病毒疫苗 |
| WO2009127988A1 (en) | 2008-04-16 | 2009-10-22 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| CN107080833A (zh) * | 2009-04-10 | 2017-08-22 | 约翰·霍普金斯大学 | 作为广谱人类乳头状瘤病毒（hpv）疫苗的乳头状瘤病毒样颗粒（vlp） |
| CN107252489A (zh) * | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| CN101890160B (zh) * | 2009-04-28 | 2014-06-18 | 北京康乐卫士生物技术有限公司 | 多价重组人乳头瘤病毒疫苗及其应用 |
| CN104288763B (zh) | 2009-06-19 | 2018-03-06 | 艾金株式会社 | 宫颈癌疫苗 |
| CA2768172A1 (en) * | 2009-06-25 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Novel compositions |
| AR074485A1 (es) * | 2009-12-04 | 2011-01-19 | Consejo Nac Invest Cient Tec | Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos |
| JP2014516075A (ja) * | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| US20130064849A1 (en) * | 2011-07-14 | 2013-03-14 | The Board Of Regents Of The University Of Texas | Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines |
| WO2013139744A1 (en) * | 2012-03-18 | 2013-09-26 | Glaxosmithkline Biologicals S.A. | Method of vaccination against human papillomavirus |
| WO2013149017A1 (en) * | 2012-03-28 | 2013-10-03 | Kansas State University Research Foundation | Vaccine adjuvant |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9974849B2 (en) | 2013-10-13 | 2018-05-22 | Bioventures, Llc | Human Papilloma virus therapeutic vaccine |
-
2015
- 2015-10-23 CN CN201580064634.6A patent/CN107001430A/zh active Pending
- 2015-10-23 MY MYPI2017000594A patent/MY195018A/en unknown
- 2015-10-23 MX MX2017005418A patent/MX395186B/es unknown
- 2015-10-23 AU AU2015335652A patent/AU2015335652B2/en active Active
- 2015-10-23 WO PCT/US2015/057150 patent/WO2016065281A1/en not_active Ceased
- 2015-10-23 JP JP2017540976A patent/JP6663438B2/ja active Active
- 2015-10-23 EP EP15853497.4A patent/EP3209676A4/en not_active Ceased
- 2015-10-23 US US14/921,648 patent/US10238729B2/en active Active
- 2015-10-23 IL IL251825A patent/IL251825B2/en unknown
- 2015-10-23 CA CA2965498A patent/CA2965498A1/en active Pending
- 2015-10-23 KR KR1020177013441A patent/KR102285401B1/ko active Active
- 2015-10-23 BR BR112017008280-2A patent/BR112017008280A2/pt not_active Application Discontinuation
- 2015-10-23 SG SG11201703262UA patent/SG11201703262UA/en unknown
-
2017
- 2017-04-24 CL CL2017001008A patent/CL2017001008A1/es unknown
- 2017-04-24 PH PH12017500754A patent/PH12017500754A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001430A (zh) | 2017-08-01 |
| AU2015335652B2 (en) | 2020-07-02 |
| EP3209676A1 (en) | 2017-08-30 |
| KR20170072279A (ko) | 2017-06-26 |
| KR102285401B1 (ko) | 2021-08-02 |
| CL2017001008A1 (es) | 2017-11-24 |
| CA2965498A1 (en) | 2016-04-28 |
| WO2016065281A1 (en) | 2016-04-28 |
| MY195018A (en) | 2023-01-03 |
| SG11201703262UA (en) | 2017-05-30 |
| PH12017500754A1 (en) | 2017-10-30 |
| JP2017531699A (ja) | 2017-10-26 |
| MX2017005418A (es) | 2017-11-30 |
| US10238729B2 (en) | 2019-03-26 |
| IL251825A0 (en) | 2017-06-29 |
| EP3209676A4 (en) | 2018-03-28 |
| IL251825B2 (en) | 2023-09-01 |
| US20160114023A1 (en) | 2016-04-28 |
| IL251825B1 (en) | 2023-05-01 |
| MX395186B (es) | 2025-03-21 |
| AU2015335652A1 (en) | 2017-05-25 |
| JP6663438B2 (ja) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ732211A (en) | Combination immunotherapy approach for treatment of cancer | |
| MX372883B (es) | Uso de anticuerpos contra claudina 18.2 para el tratamiento de cáncer. | |
| MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| NZ749218A (en) | Androgen receptor modulator and uses thereof | |
| JO3735B1 (ar) | مركبات ألكين بها استبدال رباعي واستخداماتها | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| NZ746338A (en) | Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| TN2017000554A1 (en) | Novel combination for use in the treatment of cancer | |
| AU2015329999B2 (en) | 17a,21-diesters of cortexolone for use in the treatment of tumors | |
| MX373231B (es) | Agente anticancerigeno. | |
| EP4552698A3 (en) | Methods of treating prostate cancer | |
| EP4599893A3 (en) | Cg0070 for treating bcg resistant bladder carcinoma in situ | |
| HK1258319A1 (zh) | 癌症疗法 | |
| BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
| IN2014MU00303A (https=) | ||
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| AU2016206832A8 (en) | Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| PH12018500254A1 (en) | Combinations of an ox40 antibody and a tlr4 modulator and uses thereof | |
| PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
| MY181685A (en) | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |